Aripiprazole Oral Acceptability Trial

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Local Institution, Anaheim, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Stable patients currently receiving aripiprazole or other antipsychotic medications.

Treatment and study plan

Aripiprazole

Drug

Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).

Other names: Abilify

Primary outcomes

acceptability

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Industry

Collaborators

Otsuka America Pharmaceutical

Registry information

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Jan 13, 2005
Registry last updated: Nov 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed